UNSPSC 51162654: Prenoxdiazine

This classification denotes an antitussive agent with the molecular formula C23H27N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) S491HH391H, chemically known as 1-(2-(3-(2,2-diphenylethyl)-1,2,4-oxadiazol-5-yl)ethyl)piperidine. but more generally known as prenoxdiazine, which bears US NIH Compound Identifier 120508. European Medicines Agency schedules Prenoxdiazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12421MIG.

UNSPSC 51162654 Prenoxdiazine is a Commodity code that covers pharmaceutical products purchased by state and local health agencies, particularly for emergency response and community health initiatives. Recent solicitations show state and local governments buying naloxone and related drug deactivation systems through competitive bidding processes, as well as participating in cooperative purchasing agreements for generic multi-source pharmaceuticals and over-the-counter products distributed across state and local facilities. The issuing bodies include county health departments and state-level cooperative purchasing alliances administering agreements on behalf of multiple participating jurisdictions.

Activity under the code spans Florida and Minnesota, with the most visible recent opportunities originating from county-level health procurement in Florida and multi-state cooperative purchasing administered through the Minnesota Department of Administration. Seminole County, Florida issued an IFB (solicitation IFB60459723LAS, response deadline Jul 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (solicitation S1070000015802, response deadline Mar 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with awarded vendors effective July 1, 2026, requiring compliance with current Good Manufacturing Practices, the Drug Supply Chain Security Act, and pricing through three authorized wholesalers. Both solicitations require vendors to maintain comprehensive insurance coverage, demonstrate manufacturing compliance, and provide detailed product and pricing documentation.